Basic Study
Copyright ©The Author(s) 2023.
World J Diabetes. Aug 15, 2023; 14(8): 1234-1248
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1234
Figure 4
Figure 4 Sirtuin 4 is a direct target of miR-503. A: Real-time quantitative polymerase chain reaction (RT-qPCR) verification of the validity of the ov-sirtuin 4 (SIRT4) plasmid; B: Western blot verification of the validity of the ov-SIRT4 plasmid; C: Potential binding sites of miR-503 to SIRT4; D: Dual luciferase analysis of the binding of miR-503 and SIRT4; E: RT-qPCR analysis of the effect of miR-503 mimic and ov-SIRT4 co-transfection on miR-503 expression; F: RT-qPCR analysis of the effect of miR-503 mimic and ov-SIRT4 co-transfection on SIRT4 expression. aP < 0.05 vs the ov-negative control (NC) group; bP < 0.05 vs the mimic NC group; cP < 0.05 vs the mimic group; dP < 0.05 vs the mimic + ov-NC group. miR: microRNA; NC: Negative control; RT-qPCR: Real-time quantitative polymerase chain reaction; ov: Overexpression; SIRT4: Sirtuin 4; WT: Wild type; mut: Mutant.